Cefixime
Average across 3 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.
Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.
US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.
| Labeler | Type | Packages | Status |
|---|---|---|---|
| Aurobindo Pharma Limited | unknown | 4 | SUPPLYING |
| Lupin Pharmaceuticals,Inc. | unknown | 3 | SUPPLYING |
Shortages, recalls, and registration changes attached to this drug concept.
Subpotent Drug- An out of specification ( OOS ) result observed in assay test during 18-month long term stability study. — Recalling firm: Lupin Pharmaceuticals Inc. — USA nationwide.
Failed Content Uniformity Specifications — Recalling firm: Lupin Pharmaceuticals Inc. — Nationwide in the US
Failed Impurities/Degradation Specifications — Recalling firm: Lupin Pharmaceuticals Inc. — Nationwide in the USA
Subpotent Drug — Recalling firm: Lupin Pharmaceuticals Inc. — Nationwide within the United States
Subpotent Drug: low out of specification (OOS) test result observed in long term stability study. — Recalling firm: Lupin Pharmaceuticals Inc. — Nationwide with the United States and Puerto Rico.
Pill